Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Prospects for immunocontraception in feral horse population control: exploring novel targets for an equine fertility vaccine.
Reproduction, fertility, and development    December 9, 2014   Volume 28, Issue 7 853-863 doi: 10.1071/RD14280
Swegen A, Aitken RJ.Feral horses populate vast land areas and often induce significant ecological and economic damage throughout the landscape. Non-lethal population control methods are considered favourable in light of animal welfare, social and ethical considerations; however, no single effective, safe and species-specific contraceptive agent is currently available for use in free-ranging wild and feral horses. This review explores aspects of equine reproductive physiology that may provide avenues for the development of specific and long-lasting immunocontraceptive vaccines and some of the novel strategies that...
A Systematic Review of Recent Advances in Equine Influenza Vaccination.
Vaccines    November 14, 2014   Volume 2, Issue 4 797-831 doi: 10.3390/vaccines2040797
Paillot R.Equine influenza (EI) is a major respiratory disease of horses, which is still causing substantial outbreaks worldwide despite several decades of surveillance and prevention. Alongside quarantine procedures, vaccination is widely used to prevent or limit spread of the disease. The panel of EI vaccines commercially available is probably one of the most varied, including whole inactivated virus vaccines, Immuno-Stimulating Complex adjuvanted vaccines (ISCOM and ISCOM-Matrix), a live attenuated equine influenza virus (EIV) vaccine and a recombinant poxvirus-vectored vaccine. Several other strateg...
Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine.
Australian veterinary journal    October 29, 2014   Volume 92, Issue 11 450-457 doi: 10.1111/avj.12248
Tabynov K, Kydyrbayev Z, Ryskeldinova S, Assanzhanova N, Kozhamkulov Y, Inkarbekov D, Sansyzbay A.To design and evaluate the safety and immunogenicity of a modified-live vaccine to prevent equine influenza virus (EIV) infection based on the novel reassortant cold-adapted strain A/HK/Otar/6:2/2010. Methods: Surface proteins (HA, NA) from the wild-type strain A/equine/Otar/764/2007 (H3N8) and internal proteins (PB2, PB1, PA, NP, M, NS) from the attenuated cold-adapted donor strain A/Hong Kong/1/68/162/35CA (H3N2) were included in the vaccine. Horses were administered 10(9.2) EID50 /mL of the modified-live vaccine or saline solution using a nasal spray. The clinical condition of the animals w...
Intramuscular administration of a synthetic CpG-oligodeoxynucleotide modulates functional responses of neutrophils of neonatal foals.
PloS one    October 15, 2014   Volume 9, Issue 10 e109865 doi: 10.1371/journal.pone.0109865
Cohen ND, Bourquin JR, Bordin AI, Kuskie KR, Brake CN, Weaver KB, Liu M, Felippe MJ, Kogut MH.Neutrophils play an important role in protecting against infection. Foals have age-dependent deficiencies in neutrophil function that may contribute to their predisposition to infection. Thus, we investigated the ability of a CpG-ODN formulated with Emulsigen to modulate functional responses of neutrophils in neonatal foals. Eighteen foals were randomly assigned to receive either a CpG-ODN with Emulsigen (N = 9) or saline intramuscularly at ages 1 and 7 days. At ages 1, 3, 9, 14, and 28, blood was collected and neutrophils were isolated from each foal. Neutrophils were assessed for basal and R...
New perspectives for the diagnosis, control, treatment, and prevention of strangles in horses.
The Veterinary clinics of North America. Equine practice    October 6, 2014   Volume 30, Issue 3 591-607 doi: 10.1016/j.cveq.2014.08.007
Waller AS.Strangles, characterized by abscessation of the lymph nodes of the head and neck, is the most frequently diagnosed infectious disease of horses worldwide. The persistence of the causative agent, Streptococcus equi, in a proportion of convalescent horses plays a critical role in the recurrence and spread of disease. Recent research has led to the development of effective diagnostic tests that assist the eradication of S equi from local horse populations. This article describes how these advances have been made and provides advice to assist the resolution and prevention of outbreaks. New perspec...
Detection of modified-live equine intranasal vaccine pathogens in adult horses using quantitative PCR.
The Veterinary record    October 1, 2014   Volume 175, Issue 20 510 doi: 10.1136/vr.102592
Harms C, Mapes S, Akana N, Coatti Rocha D, Pusterla N.No abstract available
Hendra virus.
The Veterinary clinics of North America. Equine practice    September 30, 2014   Volume 30, Issue 3 579-589 doi: 10.1016/j.cveq.2014.08.004
Middleton D.Hendra virus infection of horses occurred sporadically between 1994 and 2010 as a result of spill-over from the viral reservoir in Australian mainland flying-foxes, and occasional onward transmission to people also followed from exposure to affected horses. An unprecedented number of outbreaks were recorded in 2011 leading to heightened community concern. Release of an inactivated subunit vaccine for horses against Hendra virus represents the first commercially available product that is focused on mitigating the impact of a Biosafety Level 4 pathogen. Through preventing the development of acut...
Rhodococcus equi (Prescottella equi) vaccines; the future of vaccine development.
Equine veterinary journal    September 14, 2014   Volume 47, Issue 5 510-518 doi: 10.1111/evj.12310
Giles C, Vanniasinkam T, Ndi S, Barton MD.For decades researchers have been targeting prevention of Rhodococcus equi (Rhodococcus hoagui/Prescottella equi) by vaccination and the horse breeding industry has supported the ongoing efforts by researchers to develop a safe and cost effective vaccine to prevent disease in foals. Traditional vaccines including live, killed and attenuated (physical and chemical) vaccines have proved to be ineffective and more modern molecular-based vaccines including the DNA plasmid, genetically attenuated and subunit vaccines have provided inadequate protection of foals. Newer, bacterial vector vaccines hav...
Immunogenicity of an electron beam inactivated Rhodococcus equi vaccine in neonatal foals.
PloS one    August 25, 2014   Volume 9, Issue 8 e105367 doi: 10.1371/journal.pone.0105367
Bordin AI, Pillai SD, Brake C, Bagley KB, Bourquin JR, Coleman M, Oliveira FN, Mwangi W, McMurray DN, Love CC, Felippe MJ, Cohen ND.Rhodococcus equi is an important pathogen of foals that causes severe pneumonia. To date, there is no licensed vaccine effective against R. equi pneumonia of foals. The objectives of our study were to develop an electron beam (eBeam) inactivated vaccine against R. equi and evaluate its immunogenicity. A dose of eBeam irradiation that inactivated replication of R. equi while maintaining outer cell wall integrity was identified. Enteral administration of eBeam inactivated R. equi increased interferon-γ production by peripheral blood mononuclear cells in response to stimulation with virulent R. ...
Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.
Journal of virology    August 13, 2014   Volume 88, Issue 20 12077-12086 doi: 10.1128/JVI.01406-14
Reed DS, Glass PJ, Bakken RR, Barth JF, Lind CM, da Silva L, Hart MK, Rayner J, Alterson K, Custer M, Dudek J, Owens G, Kamrud KI, Parker MD, Smith J.Alphavirus replicons were evaluated as potential vaccine candidates for Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), or eastern equine encephalitis virus (EEEV) when given individually or in combination (V/W/E) to mice or cynomolgus macaques. Individual replicon vaccines or the combination V/W/E replicon vaccine elicited strong neutralizing antibodies in mice to their respective alphavirus. Protection from either subcutaneous or aerosol challenge with VEEV, WEEV, or EEEV was demonstrated out to 12 months after vaccination in mice. Individual replicon v...
Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain.
Veterinary research    August 9, 2014   Volume 45, Issue 1 82 doi: 10.1186/s13567-014-0082-y
Ma J, Wang SS, Lin YZ, Liu HF, Liu Q, Wei HM, Wang XF, Wang YH, Du C, Kong XG, Zhou JH, Wang X.The Chinese attenuated equine infectious anemia virus (EIAV) vaccine has successfully protected millions of equine animals from EIA disease in China. Given that the induction of immune protection results from the interactions between viruses and hosts, a better understanding of the characteristics of vaccine strain infection and host responses would be useful for elucidating the mechanism of the induction of immune protection by the Chinese attenuated EIAV strain. In this study, we demonstrate in equine monocyte-derived macrophages (eMDM) that EIAVFDDV13, a Chinese attenuated EIAV strain, indu...
Focus on: vaccination against equine grass sickness.
The Veterinary record    August 2, 2014   Volume 175, Issue 5 114-115 doi: 10.1136/vr.g4684
Ireland J.Jo Ireland of the Animal Health Trust describes a new field trial of a potential vaccine against equine grass sickness.
Efficacy of a Parapoxvirus ovis-based immunomodulator against equine herpesvirus type 1 and Streptococcus equi equi infections in horses.
Veterinary microbiology    July 27, 2014   Volume 173, Issue 3-4 232-240 doi: 10.1016/j.vetmic.2014.07.015
Ons E, Van Brussel L, Lane S, King V, Cullinane A, Kenna R, Lyons P, Hammond TA, Salt J, Raue R.The efficacy of Zylexis®, an immunomodulator in horses based on inactivated Parapoxvirus ovis (iPPVO), was assessed using an equine herpesvirus type 1 (EHV-1) challenge model in the presence of a natural infection with Streptococcus equi equi (S. equi). Eleven horses were treated with iPPVO and twelve were kept as controls. Six horses were challenged with EHV-1 and commingled with the horses on study. Animals were dosed on Days -2, 0 (just before commingling) and Day 7. On Day 11 significantly less nasal discharge, enlarged lymph nodes, EHV-1 shedding and lower rectal temperatures were observ...
CpG-ODN class C-mediated immunostimulation and its potential against Trypanosoma evansi in equines.
International immunopharmacology    July 24, 2014   Volume 22, Issue 2 366-370 doi: 10.1016/j.intimp.2014.07.016
Manuja A, Kumar P, Kumar R, Kumar B, Singha H, Sharma RK, Yadav SC.Trypanosoma evansi is the causative agent of surra, which is the most common and widespread trypansomal disease. The infection is mainly restricted to animals, but it has also been documented in human. Trypanosomes possess the thick immunogenic surface coat known as variant surface glycoprotein (VSG). The parasite modifies the VSG constantly resulting in continuous antigenic variations and thus evades the host immune response. Due to antigenic variations, vaccination against trypanosomosis is not useful. Therefore, alternate strategies to augment the immune response are required. CpG-ODN class...
Structural and antigenic features of the synthetic SF23 peptide corresponding to the receptor binding fragment of diphtheria toxin.
Molecular immunology    July 23, 2014   Volume 63, Issue 2 235-244 doi: 10.1016/j.molimm.2014.07.008
Khrustaleva TA, Khrustalev VV, Barkovsky EV, Kolodkina VL, Astapov AA.The SF23 peptide corresponding to the receptor binding fragment of diphtheria toxin (residues 508-530) has been synthesized. This fragment forming a protruding beta hairpin has been chosen because it is the less mutable B-cell epitope. Affine chromatography and ELISA show that antibodies from the sera of persons infected by toxigenic Corynebacterium diphtheriae and those immunized by diphtheria toxoid are able to bind the synthetic SF23 peptide. There are antibodies recognizing the SF23 peptide in the serum of horses hyperimmunized with diphtheria toxoid. Analysis of circular dichroism spectra...
Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.
Vaccine    July 18, 2014   Volume 32, Issue 39 4932-4937 doi: 10.1016/j.vaccine.2014.07.031
Kanai Y, van Rijn PA, Maris-Veldhuis M, Kaname Y, Athmaram TN, Roy P.African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides. AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and t...
A brief introduction to equine influenza and equine influenza viruses.
Methods in molecular biology (Clifton, N.J.)    June 6, 2014   Volume 1161 365-370 doi: 10.1007/978-1-4939-0758-8_31
Chambers TM.Equine influenza virus (EIV) is a common respiratory pathogen of horses and other equids in most parts of the world. EIV are Type A influenza viruses and two subtypes are known: H3N8 and H7N7. Both are believed to have evolved from avian influenza virus ancestors. The H3N8 subtype circulates widely, but the H7N7 subtype is thought to be extinct. The clinical disease in horses, caused by either subtype, is an upper respiratory infection of varying severity depending upon the immune status of the individual animal. It is not normally life-threatening in itself except in very young foals; however...
The potential impact of a single amino-acid substitution on the efficacy of equine influenza vaccines.
Equine veterinary journal    June 3, 2014   Volume 47, Issue 4 456-462 doi: 10.1111/evj.12290
Yamanaka T, Cullinane A, Gildea S, Bannai H, Nemoto M, Tsujimura K, Kondo T, Matsumura T.The protection induced by an equine influenza (EI) vaccine strain depends on its antigenic relatedness to the challenge virus. Although the World Organisation for Animal Health (OIE) recommend that both Florida sublineage clade 1 (Fc1) and clade 2 (Fc2) viruses should be included in EI vaccines, Japanese EI vaccines have not, thus far, been updated to include a Fc2 virus. Objective: To evaluate the efficacy of antibodies raised against Japanese EI vaccine strains in the neutralisation of recent Fc2 viruses. Methods: Antigenic analysis. Methods: Virus neutralisation tests were performed using a...
Innovative immunization protocols using chimeric recombinant protein for the production of polyspecific loxoscelic antivenom in horses.
Toxicon : official journal of the International Society on Toxinology    May 28, 2014   Volume 86 59-67 doi: 10.1016/j.toxicon.2014.05.007
Figueiredo LF, Dias-Lopes C, Alvarenga LM, Mendes TM, Machado-de-Ávila RA, McCormack J, Minozzo JC, Kalapothakis E, Chávez-Olórtegui C.A chimeric protein (rCpLi) was constructed expressing three epitopes of rLiD1, a dermonecrotic toxin from the venom of Loxosceles intermedia spider. We have analyzed the neutralization potential of sera obtained by immunization of horses with rCpLi and rCpLi combined with initial doses of venoms and compared these with antivenom traditionally produced in horses using crude Loxosceles gaucho, Loxosceles laeta and L. intermedia venoms as antigens. We have demonstrated by ELISA that horses immunized with three initial doses of crude venom containing mixtures of L. intermedia, L. gaucho and L. lae...
Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.
Vaccines    May 27, 2014   Volume 2, Issue 2 397-421 doi: 10.3390/vaccines2020397
Schwartz EJ, Smith RJ.The ability to predict the conditions under which antibodies protect against viral infection would transform our approach to vaccine development. A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine. Recently, an example of antibody-mediated vaccine protection has been shown via passive transfer of neutralizing antibodies before equine infectious anemia virus (EIAV) infection of horses with severe combined immunodeficiency (SCID). Viral dynamic modeling of antibody protection from EIAV ...
Immediate-early protein of equid herpesvirus type 1 as a target for cytotoxic T-lymphocytes in the Thoroughbred horse.
The Journal of general virology    May 16, 2014   Volume 95, Issue Pt 8 1783-1789 doi: 10.1099/vir.0.065888-0
Kydd JH, Case R, Minke J, Audonnet JC, Wagner B, Antczak DF.Cytotoxic T-lymphocytes (CTLs) are associated with protective immunity against disease caused by equid herpesvirus type 1 (EHV-1). However, the EHV-1 target proteins for CTLs are poorly defined. This limits the development of vaccine candidates designed to stimulate strong CTL immunity. Here, classical CTL assays using lymphocytes from horses of three defined MHC class I types that experienced natural infection with EHV-1 and a modified vaccinia virus construct containing an EHV-1 gene encoding the immediate-early (IE) protein are reported. Horses homozygous for the equine leukocyte antigen (E...
Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
Vaccine    May 14, 2014   Volume 32, Issue 29 3670-3674 doi: 10.1016/j.vaccine.2014.04.036
Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L, Gubbins S, Urniza A, Mertens P, Castillo-Olivares J.African horse sickness virus (AHSV) is an arthropod-borne pathogen that infects all species of equidae and causes high mortality in horses. Previously, a recombinant modified vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 was shown to induce virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR -/-) against virulent AHSV challenge. This study builds on the previous work, examining the protective efficacy of MVA-VP2 vaccination in the natural host of AHSV infection. A study group of 4 horses was vaccinated twice wit...
Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
Vaccine    May 9, 2014   Volume 32, Issue 29 3611-3616 doi: 10.1016/j.vaccine.2014.04.087
Crafford JE, Lourens CW, Smit TK, Gardner IA, MacLachlan NJ, Guthrie AJ.African horse sickness (AHS) is typically a highly fatal disease in susceptible horses and vaccination is currently used to prevent the occurrence of disease in endemic areas. Similarly, vaccination has been central to the control of incursions of African horse sickness virus (AHSV) into previously unaffected areas and will likely play a significant role in any future incursions. Horses in the AHSV-infected area in South Africa are vaccinated annually with a live-attenuated (modified-live virus [MLV]) vaccine, which includes a cocktail of serotypes 1, 3, 4 (bottle 1) and 2, 6-8 (bottle 2) deli...
Efficacy of a non-updated, Matrix-C-based equine influenza subunit-tetanus vaccine following Florida sublineage clade 2 challenge.
The Veterinary record    May 2, 2014   Volume 174, Issue 25 633 doi: 10.1136/vr.101993
Pouwels HG, Van de Zande SM, Horspool LJ, Hoeijmakers MJ.Assessing the ability of current equine influenza vaccines to provide cross-protection against emerging strains is important. Horses not vaccinated previously and seronegative for equine influenza based on haemagglutination inhibition (HI) assay were assigned at random to vaccinated (n=7) or non-vaccinated (control, n=5) groups. Vaccination was performed twice four weeks apart with a 1 ml influenza subunit (A/eq/Prague/1/56, A/eq/Newmarket/1/93, A/eq/Newmarket/2/93), tetanus toxoid vaccine with Matrix-C adjuvant (EquilisPrequenza Te). All the horses were challenged individually by aerosol wi...
Mouse lung infection model to assess Rhodococcus equi virulence and vaccine protection.
Veterinary microbiology    March 30, 2014   Volume 172, Issue 1-2 256-264 doi: 10.1016/j.vetmic.2014.03.026
González-Iglesias P, Scortti M, MacArthur I, Hapeshi A, Rodriguez H, Prescott JF, Vazquez-Boland JA.The pathogenic actinomycete Rhodococcus equi causes severe purulent lung infections in foals and immunocompromised people. Although relatively unsusceptible to R. equi, mice are widely used for in vivo studies with this pathogen. The most commonly employed mouse model is based on systemic (intravenous) infection and determination of R. equi burdens in spleen and liver. Here, we investigated the murine lung for experimental infection studies with R. equi. Using a 10(7)CFU intranasal challenge in BALB/c mice, virulent R. equi consistently survived in quantifiable numbers up to 10 days in the lun...
Structural and biochemical insights into the V/I505T mutation found in the EIAV gp45 vaccine strain.
Retrovirology    March 21, 2014   Volume 11 26 doi: 10.1186/1742-4690-11-26
Du J, Wang X, Ma J, Wang J, Qin Y, Zhu C, Liu F, Shao Y, Zhou J, Qiao W, Liu X.The equine infectious anemia virus (EIAV) is a lentivirus of the Retrovirus family, which causes persistent infection in horses often characterized by recurrent episodes of high fever. It has a similar morphology and life cycle to the human immunodeficiency virus (HIV). Its transmembrane glycoprotein, gp45 (analogous to gp41 in HIV), mediates membrane fusion during the infection. However, the post-fusion conformation of EIAV gp45 has not yet been determined. EIAV is the first member of the lentiviruses for which an effective vaccine has been successfully developed. The attenuated vaccine strai...
Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health.
Emerging infectious diseases    February 28, 2014   Volume 20, Issue 3 372-379 doi: 10.3201/eid2003.131159
Middleton D, Pallister J, Klein R, Feng YR, Haining J, Arkinstall R, Frazer L, Huang JA, Edwards N, Wareing M, Elhay M, Hashmi Z, Bingham J, Yamada M....In recent years, the emergence of several highly pathogenic zoonotic diseases in humans has led to a renewed emphasis on the interconnectedness of human, animal, and environmental health, otherwise known as One Health. For example, Hendra virus (HeV), a zoonotic paramyxovirus, was discovered in 1994, and since then, infections have occurred in 7 humans, each of whom had a strong epidemiologic link to similarly affected horses. As a consequence of these outbreaks, eradication of bat populations was discussed, despite their crucial environmental roles in pollination and reduction of the insect p...
Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus.
Journal of virological methods    February 5, 2014   Volume 200 22-28 doi: 10.1016/j.jviromet.2014.01.010
McNabb L, Barr J, Crameri G, Juzva S, Riddell S, Colling A, Boyd V, Broder C, Wang LF, Lunt R.Hendra and Nipah viruses (HeV and NiV) are closely related zoonotic pathogens of the Paramyxoviridae family. Both viruses belong to the Henipavirus genus and cause fatal disease in animals and humans, though only HeV is endemic in Australia. In general and due to the acute nature of the disease, agent detection by PCR and virus isolation are the primary tools for diagnostic investigations. Assays for the detection of antibodies against HeV are fit more readily for the purpose of surveillance testing in disease epidemiology and to meet certification requirements in the international movement of...
Long-term methods and effects of remotely treating wildlife with immunocontraception.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians    January 21, 2014   Volume 44, Issue 4 Suppl S138-S140 doi: 10.1638/1042-7260-44.4S.S138
Naugle R, Grams K.The development of sophisticated delivery equipment, as well as safer and more effective drugs, has made remote delivery of animal drugs a standard and readily available tool for wildlife professionals, veterinarians, ranchers, and animal control officers. In the 1980s, researchers began treating a wide variety of wildlife with injectable porcine zona pellucida immunocontraceptive vaccines. Remote delivery of immunocontraceptives has been proven effective at the individual and population level for wild horses and urban deer. However, it took only a short time at each study site to understand t...
Expression of the hemagglutinin HA1 subunit of the equine influenza virus using a baculovirus expression system.
Revista Argentina de microbiologia    January 10, 2014   Volume 45, Issue 4 222-228 doi: 10.1016/S0325-7541(13)70028-2
Sguazza GH, Fuentealba NA, Tizzano MA, Galosi CM, Pecoraro MR.Equine influenza virus is a leading cause of respiratory disease in horses worldwide. Disease prevention is by vaccination with inactivated whole virus vaccines. Most current influenza vaccines are generated in embryonated hens' eggs. Virions are harvested from allantoic fluid and chemically inactivated. Although this system has served well over the years, the use of eggs as the substrate for vaccine production has several well-recognized disadvantages (cost, egg supply, waste disposal and yield in eggs). The aim of this study was to evaluate a baculovirus system as a potential method for prod...
1 10 11 12 13 14 35